Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261615 | 0.72 | CYP2C9 (0.38) | CYP2C9CYP2C19CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL9250688 | 0.71 | HCAR2 (0.39) | SMN1; SMN2DAOHCAR2 | |
| SCHEMBL3264081 | 0.70 | CYP2C9 (0.37) | CYP2C9CYP2C19CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL2725056 | 0.69 | — | — | |
| SCHEMBL17646502 | 0.65 | BTK (0.40) | CYP2C9CYP2C19CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL3261931 | 0.64 | ALDH1A1 (0.40) | CYP2C9CYP2C19CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL10153743 | 0.64 | HTR1B (0.53) | — | |
| SCHEMBL3395966 | 0.64 | L3MBTL4 (0.39) | CYP2C9CYP2C19CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL9933898 | 0.64 | — | — | |
| SCHEMBL9935599 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029625-A1 | Therapeutic Agent for Restenosis | NR1H2, NR1H3, LDLR | CYP2C9 2518/4885CYP2C19 1888/4885CYP1A2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.